

## Electronic Supplementary Information

### Chiral Brønsted Acid-Catalyzed Intramolecular S<sub>N</sub>2' Reaction for Enantioselective Construction of Quaternary Stereogenic Center

Masahiro Shimizu,<sup>a</sup> Jun Kikuchi,<sup>a</sup> Azusa Kondoh,<sup>b</sup> Masahiro Terada\*<sup>a</sup>

e-mail: mterada@m.tohoku.ac.jp

<sup>a</sup>Department of Chemistry, Graduate School of Science, Tohoku University,

Sendai 980-8578, Japan

<sup>b</sup>Research and Analytical Center for Giant Molecules, Graduate School of Science,  
Tohoku University, Sendai 980-8578, Japan

#### Contents:

1. General Information.
2. Preparation of Catalysts
3. Preparation of Starting Materials
4. Enantioselective S<sub>N</sub>2' Reaction Catalyzed by Chiral Brønsted Acids
5. Additional Screenings
6. Derivatization of Product
7. Mechanistic Study
8. DFT Calculation
9. References
10. NMR Spectra
11. HPLC Charts

## 1. General Information


### 1-1. Instruments and materials

<sup>1</sup>H NMR spectra were recorded on a JEOL ECA-600 (600 MHz) or JEOL ECA-700 (700 MHz) spectrometer at ambient temperature. <sup>2</sup>H NMR spectra were recorded on a JEOL ECA-700 (700 MHz) spectrometer at ambient temperature. Chemical shifts are reported in ppm, with solvent resonance employed as internal standard; CDCl<sub>3</sub> (7.26 ppm), C<sub>6</sub>D<sub>6</sub> (7.16 ppm), and acetone-d<sub>6</sub> (2.06 ppm). <sup>13</sup>C NMR spectra were recorded on a JEOL ECA-600 (151 Hz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from the solvent resonance as the internal standard; CDCl<sub>3</sub> (77.0 ppm), C<sub>6</sub>D<sub>6</sub> (128.0 ppm), and acetone-d<sub>6</sub> (206.7 ppm, 29.9 ppm). <sup>19</sup>F NMR spectra were recorded on a JEOL ECA-600 (565 MHz). Chemical shifts are reported in ppm from the C<sub>6</sub>H<sub>5</sub>CF<sub>3</sub> (-67.2 ppm) resonance as the external standard. <sup>31</sup>P NMR spectra were recorded on a JEOL ECA-600 (243 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from the PPh<sub>3</sub> (-6 ppm) resonance as the external standard. Infrared spectra were recorded on a Jasco FT/IR-4100 spectrometer. Optical rotations were measured on a Jasco P-1020 digital polarimeter with a sodium lamp and reported as follows; [α]<sup>T</sup> <sup>°C</sup><sub>D</sub> (*c* = g/100 mL, solvent, % ee). Chiral stationary phase HPLC analysis was performed on a Jasco LC-2000 Plus Series system. High-resolution mass spectra analysis was performed on a Bruker Daltonics solariX 9.4T spectrometer at the Research and Analytical Center for Giant Molecules, Graduate School of Science, Tohoku University.

### 1-2. Material and methods

CH<sub>2</sub>Cl<sub>2</sub>, toluene, Et<sub>2</sub>O and THF were supplied from Kanto Chemical Co., Inc. as “Dehydrated solvent system”. Other solvents were dried over activated MS4A and used under nitrogen atmosphere. Reagents were purchased from commercial suppliers and used without further purification. All reactions were carried out in flame-dried glassware with magnetic stirring under nitrogen atmosphere. Analytical thin layer chromatography (TLC) was performed on Merck pre-coated TLC plates (silica gel 60 GF 254, 0.25 mm). Purification of reaction products was carried out by flash column chromatography using silica gel 60 (spherical, neutral, 100-210 μm; KANTO Chemical Co., Inc.), silica gel 60 (230-400 mesh; E. Merk), and DIOL silica gel (45-75 μm; Fuji Silysia Chemical Ltd.). NH silica gel (45-75 μm; Fuji Silysia Chemical Ltd.).


## 2. Preparation of Catalysts



**Potassium 1,3,4,5,6,7,8-heptafluoronaphthalene-2-sulfonate (S2):** In a flame dried flask with reflux condenser under  $N_2$ , perfluoronaphthalene (**S1**) (2.7 g, 10 mmol, 1.0 equiv) and  $K_2SO_3$  (1.9g, 12 mmol, 1.2 equiv) was dissolved in DMF (50 mL, 0.2 M) and  $H_2O$  (5 mL, 2.0 M). The mixture was stirred at  $120^\circ C$  for 24 h, then the reaction mixture was concentrated. The residual mixture was dissolved in  $H_2O$  (40 mL) and Acetone (20 mL) after cooled to room temperature. Then acetone in the residual mixture was removed under reduced pressure. To the residual suspension was added  $CH_2Cl_2$  (20 mL) and filtered to give the crude of **S2** (1.7g, 46% yield) as a brown solid. The crude was used without further purification.


**1,3,4,5,6,7,8-heptafluoronaphthalene-2-sulfonate (S2):**  $^{13}C$  NMR could not be measured due to low solubility in any solvent.  $^{19}F$  NMR (565 MHz, Acetone-d<sub>6</sub>):  $\delta$  -115.4 (dd,  $J = 77.5, 16.7$  Hz, 1F), -134.1 (d,  $J = 16.7$  Hz, 1F), -145.69 (dt,  $J = 76.3, 16.7$  Hz, 1F), -149.3 (dt,  $J = 57.2, 16.7$  Hz, 1F), -152.3 (dt,  $J = 57.2, 16.7$  Hz, 1F), -156.7 (t,  $J = 16.7$  Hz, 1F), -159.5 (m, 1F); IR(neat,  $cm^{-1}$ ): 3282, 3056, 2924, 1644, 1603, 1490, 1418, 1316, 1228, 1184, 1102, 959, 912; HRMS(ESI+): Calcd for  $C_{10}F_7K_2O_3S$ , ([M + K]<sup>+</sup>) 410.8731, Found, 410.8725.

**1,3,4,5,6,7,8-heptafluoronaphthalene-2-sulfonamide (S3):** To a suspension of **S2** (856 mg, 2.3 mmol, 1.0 equiv) in  $SOCl_2$  (2.3 mL, 1.0 M) and toluene (2.3 mL, 1.0 M) was added DMF (230  $\mu$ L, 3.0 mmol, 1.3 equiv) at  $0^\circ C$ . After stirring at  $60^\circ C$  for 2 h, the mixture was cooled to  $0^\circ C$  and carefully poured the ice cold water. Then the mixture was extracted with  $Et_2O$  to give the crude of sulfonylchloride as a brown solid. The crude of sulfonylchloride was dissolved in  $CH_2Cl_2$  (9.2 mL, 0.25M) and added 30%  $NH_3$  aq (767  $\mu$ L, 11.5 mmol 5 equiv). After stirring at room temperature for 30 min, the mixture was directly purified by column chromatography on silica gel (Hexane/EtOAc = 7/1) to provide **S3** (239 mg, 0.72 mmol) in 31% yield (2 steps) as a colorless solid.




<sup>1</sup>H NMR (600 MHz, Acetone-d<sub>6</sub>): δ 7.56 (brs, 2H); <sup>19</sup>F NMR (565 MHz, Acetone-d<sub>6</sub>): δ -114.8 (dd, *J* = 76.3, 16.7 Hz, 1F), 138.2 (m, 1F), -144.1 (dm, *J* = 73.9 Hz, 1F), -147.6 (dm, *J* = 59.6 Hz, 1F), -149.1 (dm, *J* = 59.6 Hz, 1F), -152.3 (m, 1F), -156.4 (m, 1F); <sup>13</sup>C NMR (151 MHz, Acetone-d<sub>6</sub>): δ 150.8 (dm, *J* = 266 Hz, 1C), 144.6 (ddm, *J* = 262, 13.7 Hz, 1C), 144.8 (dm, *J* = 252 Hz, 1C), 142.0 (dm, *J* = 250 Hz, 3C), 140.3 (dm, *J* = 254 Hz, 1C), 122.5 (m, 1C), 113.7 (m, 1C), 109.1 (m, 1C); IR(neat, cm<sup>-1</sup>): 3407, 3291, 1653, 1605, 1532, 1497, 1407, 1365, 1265, 1175, 1115, 963, 904; HRMS(ESI+): Calcd for C<sub>10</sub>H<sub>2</sub>F<sub>7</sub>NNaO<sub>2</sub>S, ([M + Na]<sup>+</sup>) 335.9592, Found, 335.9587.

**N-((2*r*,11*b**R*)-2,6-di(anthracen-9-yl)-4-oxodinaphtho[2,1-*d*:1',2'-*f*][1,3,2]dioxaphosphepin-4-yl)-1,3,4,5,6,7,8-heptafluoronaphthalene-2-sulfonamide ((*R*)-3d):** In a flame dried flask under N<sub>2</sub>, PCl<sub>5</sub> (83 mg, 0.4 mmol, 1.37 equiv) and **S3** (127 mg, 0.38 mmol, 1.3 equiv) were dissolved in toluene (1.9 mL, 0.25 M) and THF (76 μL, 5.0 M). The mixture was stirred at 50 °C for 2 h and concentrated. To the resulting mixture were added pyridine (2.9 mL), **S4** (185 mg, 0.29 mmol, 1.0 equiv) and NEt<sub>3</sub> (407 μL, 0.29 mmol, 10 equiv) at 0°C. After the reaction mixture was stirred for 2 h, quenched with 1 N HCl aq and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extracts were washed with brine and concentrated. Then the residual crude was purified by flash column chromatography on silica gel (Hexane/Acetone = 5/1 to 2/1), acidified with 6 N HCl (2 mL) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL), followed by drying under reduced pressure afforded compound (*R*)-3d (180 mg, 61%) as a yellow powder.



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.63 (s, 1H), 8.24-7.95 (m, 8H), 7.75-7.30 (m, 17H), 7.22-7.09 (m, 2H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 150.1 (dm, *J* = 279 Hz, 1C), 149.2, 146.0, 145.9, 144.5, 144.4-138.1 (m, 6C), 134.44, 134.40, 132.6, 132.4, 132.0, 131.8, 131.6, 131.3, 131.0, 130.9, 130.8, 130.5, 130.4, 129.9, 129.8, 129.7, 129.6, 129.4, 128.8, 128.7, 128.5, 128.4, 127.74, 127.71, 127.52, 127.46, 127.42, 127.36, 126.9, 126.8, 126.7, 126.5, 126.0, 125.8, 125.41, 125.39, 125.2, 124.98, 124.95, 124.8, 124.4, 122.4, 122.0, 117.5 (m), 113.0 (m), 106.7 (m); <sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>): δ -110.7 (dd, *J* = 77.5, 16.7 Hz, 1F), -136.7 (dm, *J* = 11.9 Hz, 1F), -140.0 (dm, *J* = 76.3 Hz, 1F), -144.7 (dt, *J* = 57.2, 16.7 Hz, 1F), -145.8 (dt, *J* = 59.6, 16.7 Hz, 1F), -148.7 (m, 1F), -153.8 (m, 1F); <sup>31</sup>P NMR (243 MHz, CDCl<sub>3</sub>): δ -5.63; IR(neat, cm<sup>-1</sup>): 3282, 3056, 2924, 1644, 1603, 1490, 1418, 1316, 1228, 1184, 1102, 959, 912; HRMS(ESI-): Calcd for C<sub>58</sub>H<sub>28</sub>F<sub>7</sub>NO<sub>5</sub>PS, [M - H]<sup>+</sup>, 1014.1314; found, 1014.1317.


**N-((2*r*,11*b**R*)-2,6-di(anthracen-9-yl)-4-oxidodinaphtho[2,1-*d*:1',2'-*f*][1,3,2]dioxaphosphhepin-4-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide ((*R*)-3c):** (*R*)-3c was synthesized according to the same procedure of (*R*)-3d :<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.61 (s, 1H), 8.47 (s, 1H), 8.22 (s, 1H), 8.11-8.02 (m, 6H), 7.92 (d, *J* = 8.6 Hz, 1H), 7.74-7.30 (m, 17H), 7.19 (t, *J* = 7.6 Hz, 1H);<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 145.93, 145.86, 144.4, 144.3, 143.7 (dm, *J* = 262 Hz, 4C), 136.7 (dm, *J* = 254 Hz, 1C), 134.5, 134.3, 132.6, 132.4, 132.1, 131.8, 131.6, 131.24, 131.24, 130.9, 130.8, 130.7, 130.6, 130.5, 130.1, 129.8, 129.5, 129.4, 128.8, 128.7, 128.6, 128.5, 127.7, 127.5, 127.42, 127.38, 127.11, 127.09, 126.84, 126.79, 126.5, 126.0, 125.9, 125.4, 125.3, 125.2, 125.1, 125.0, 124.8, 124.5, 122.4, 121.9, 115.2 (m, 1C), two carbons were not found probably due to overlapping.;<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>): δ -136.7 (d, *J* = 19.1 Hz, 2F), -143.9 (m, 1F), -158.9 (t, *J* = 19.1 Hz, 1F);<sup>31</sup>P NMR (243 MHz, CDCl<sub>3</sub>): δ -5.92; IR(neat, cm<sup>-1</sup>): 3056, 2360, 1723, 1644, 1499, 1403, 1300, 1227, 1180, 1100, 988, 889, 751; HRMS(ESI-): Calcd for C<sub>54</sub>H<sub>28</sub>F<sub>5</sub>NO<sub>5</sub>PS, [M - H]<sup>-</sup>, 928.1346; found, 928.1350.



### 3. Preparation of Starting Materials


#### 3-1. General procedure for the preparation of 2-substituted but-2-ene-1,4-diols (**S6**)

Method A<sup>1</sup>: for the preparation of **1a~1h**, **1j**, **1l~1o**




To a solution of PhMgBr (20.0 mL, 1.0 M solution in Et<sub>2</sub>O, 20.0 mmol) in Et<sub>2</sub>O (20 mL) solution was added but-2-yne-1,4-diol **S5** (1.05 g, 5.0 mmol) in THF (10 mL) dropwise. The reaction mixture was stirred at 50 °C for overnight. Then the reaction mixture was cooled to 0 °C and quenched with H<sub>2</sub>O and 3 M HCl aq. Then the resulting mixture was extracted with EtOAc and concentrated. The residual crude was purified by flash column chromatography on silica gel (Hexane/EtOAc = 4/1 to EtOAc only) to provide (2E)-2-phenylbut-2-ene-1,4-diol **S6** (608 mg, 3.7 mmol, 74% yield) as a yellow oil.

Method B<sup>2</sup>: for the preparation of **1i**, **1k**



**S9** was synthesized according to the reported procedure.<sup>2</sup>


#### 3-2. General procedure for the synthesis of bis-imidates: preparation of (*E*)-2-phenylbut-2-ene-1,4-diyil bis(2,2,2-trichloroacetimidate) (**1a**)




To a solution of **S6** (164 mg, 1.0 mmol) and trichloroacetonitrile (250 μL, 2.5 mmol, 2.5 eq) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added DBU (30 μL, 0.2 mmol, 20 mol%) at 0 °C. The resulting solution was stirred for 2 h. Then the residual crude was concentrated and purified by flash column chromatography (Hexane/EtOAc = 20/1) to give the product **1a** (408 mg, 0.9 mmol, 90% yield) as a colorless oil.

### 3-3. Spectral data of starting materials


**(E)-2-phenylbut-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1a):** colorless oil;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$




**(E)-2-(4-methoxyphenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1b):** colorless oil;  $^1\text{H}$  NMR (600




**(E)-2-(p-tolyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1c):** colorless oil;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )




**(E)-2-(4-chlorophenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1d):** colorless oil;  $^1\text{H}$  NMR (600 MHz,




**(E)-2-(3-methoxyphenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1e):** colorless oil;  $^1\text{H}$  NMR (600




**(E)-2-(m-tolyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1f):** colorless oil;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )




**(E)-2-(3-chlorophenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1g):** colorless oil;  $^1\text{H}$  NMR (600 MHz,




**(E)-2-(3-(trifluoromethyl)phenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1h):** colorless oil;  $^1\text{H}$  NMR



**(E)-2-(2-methoxyphenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1i):** colorless oil;  $^1\text{H}$  NMR (600




**(E)-2-(2-fluorophenyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1j):** colorless oil;  $^1\text{H}$  NMR (600 MHz,




492.8804, Found, 492.8799.

**(E)-2-(naphthalen-2-yl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1k):** colorless solid;  $^1\text{H}$  NMR (600




Calcd for  $\text{C}_{18}\text{H}_{14}\text{Cl}_6\text{N}_2\text{NaO}_2$ ,  $[\text{M} + \text{Na}]^+$  522.9084, Found, 522.9079.

**(E)-2-(phenylethynyl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1m):** colorless oil;  $^1\text{H}$  NMR (600 MHz,



1297, 1072, 991, 827; HRMS (ESI $^+$ ) Calcd for  $\text{C}_{16}\text{H}_{12}\text{Cl}_6\text{N}_2\text{NaO}_2$ ,  $[\text{M} + \text{Na}]^+$  496.8928, Found, 496.8922.


**(E)-2-(thiophen-3-yl)but-2-ene-1,4-diyI bis(2,2,2-trichloroacetimidate) (1n):** colorless oil;  $^1\text{H}$  NMR (600 MHz,



HRMS (ESI $^+$ ) Calcd for  $\text{C}_{12}\text{H}_{10}\text{Cl}_6\text{N}_2\text{NaO}_2\text{S}$ ,  $[\text{M} + \text{Na}]^+$  480.8462, Found, 480.8457.

## 4. Enantioselective $S_N2'$ Reaction Catalyzed by Chiral Brønsted Acids

### 4-1. Representative procedure



To a CHCl<sub>3</sub> (1.0 mL) solution of **1** (0.1 mmol, 1.0 equiv.) and MS4A (50 mg) was added (*R*)-**3d** (10 mg, 0.01 mmol, 10 mol%) at indicated temperature and the reaction mixture was quenched with NEt<sub>3</sub> (10  $\mu$ L) at indicated time (monitored by TLC). The reaction mixture was directly purified by flash silica gel column chromatography to give **2**. The enantiomeric excess of **2** was determined by chiral stationary phase HPLC analysis.

### 4-2. Spectral data of products

**(R)-4-phenyl-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2a):** Prepared according to the representative procedure over the course of 48 h at -60 °C.; Colorless oil (85% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 8.34 (minor), 8.98 (major) min, (95% ee);  $[\alpha]^{22.0}_D = +53.2$  ( $c = 0.8$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.40-7.35 (m, 4H), 7.31 (tt,  $J = 7.2$ , 1.8 Hz, 1H), 6.20 (dd,  $J = 17.4$ , 10.8 Hz, 1H), 5.31 (d,  $J = 10.8$  Hz, 1H), 5.27 (d,  $J = 17.4$  Hz, 1H), 4.92 (d,  $J = 8.4$  Hz, 1H), 4.66 (d,  $J = 8.4$  Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  162.1, 142.7, 139.7, 128.8, 127.7, 125.8, 115.2, 86.6, 81.1, 77.9; IR (ATR, cm<sup>-1</sup>): 3090, 3022, 2959, 2924, 1905, 1728, 1662, 1637, 1513, 1471, 1405, 1379, 1351, 1270, 1186, 1116, 1074, 1039, 996, 938, 899, 842, 821; HRMS (ESI+) Calcd for C<sub>12</sub>H<sub>10</sub>Cl<sub>3</sub>NNaO, ([M + Na]<sup>+</sup>) 311.9726, Found, 311.9720.

**(R)-4-(4-methoxyphenyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2b):** Prepared according to the representative procedure over the course of 12 h at -60 °C.; White solid (98% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 14.1 (major), 15.4 (minor) min, (79% ee);  $[\alpha]^{21.5}_D = +38.5$  ( $c = 1.0$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.29-7.26 (m, 2H), 6.92-6.89 (m, 2H), 6.18 (dd,  $J = 17.4$ , 10.8 Hz, 1H), 5.30 (d,  $J = 10.2$  Hz, 1H), 5.25 (d,  $J = 17.4$  Hz, 1H), 4.88 (d,  $J = 8.4$  Hz, 1H), 4.63 (d,  $J = 7.8$  Hz, 1H), 3.81 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  162.0, 159.1, 139.8, 134.8, 127.1, 115.1, 114.1, 86.7, 81.2, 77.5, 55.3; IR (ATR, cm<sup>-1</sup>): 3004, 2957, 2934, 2908, 2837, 2047, 1888, 1728, 1662, 1637, 1711, 1682, 1511, 1465, 1442, 1405, 1351, 1302, 1250, 1179, 1115, 1074, 1034, 996, 944, 888, 832; HRMS (ESI+) Calcd for C<sub>13</sub>H<sub>12</sub>Cl<sub>3</sub>NNaO<sub>2</sub>, ([M + Na]<sup>+</sup>) 341.9831, Found, 341.9826.

**(R)-4-(p-tolyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2c):** Prepared according to the representative procedure over the course of 12 h at -60 °C.; Colorless oil (96% yield); HPLC analysis Chiralcel OB-H (Only hexane, 1.0 mL/min, 220 nm, 40 °C) 7.38 (minor), 8.83 (major) min, (90% ee);  $[\alpha]^{21.9}_D = +22.9$  ( $c = 0.8$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.25-7.18 (m, 4H), 6.19 (dd,  $J = 17.4$ , 10.8 Hz, 1H), 5.29 (d,  $J = 10.2$  Hz, 1H), 5.25 (d,  $J = 17.4$  Hz, 1H), 4.89 (d,  $J = 7.8$  Hz, 1H), 4.64 (d,  $J = 8.4$  Hz, 1H), 2.35 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  162.0, 139.94, 139.86, 137.5, 129.4, 125.7,

115.1, 86.7, 81.2, 77.8, 21.0; IR (ATR, cm<sup>-1</sup>): 3568, 3390, 3091, 2959, 2924, 1905, 1728, 1663, 1637, 1513, 1471, 1406, 1351, 1270, 1186, 1116, 1074, 997, 939, 843, 821; HRMS (ESI+) Calcd for C<sub>13</sub>H<sub>12</sub>Cl<sub>3</sub>NNaO, ([M + Na]<sup>+</sup>) 325.9882, Found, 325.9877.

**(R)-4-(4-chlorophenyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2d):** Prepared according to the representative procedure over the course of 48 h at -50 °C.; Colorless oil (90% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 8.98 (minor), 9.64 (major) min, (91% ee); [α]<sup>21.9</sup><sub>D</sub> = +21.5 (c = 1.2, CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.37-7.33 (m, 2H), 7.32-7.27 (m, 2H), 6.15 (dd, J = 17.4, 10.8 Hz, 1H), 5.32 (d, J = 10.8 Hz, 1H), 5.26 (d, J = 16.8 Hz, 1H), 4.91 (d, J = 10.4 Hz, 1H), 4.61 (d, J = 10.4 Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.4, 141.2, 139.3, 133.7, 128.9, 127.3, 115.7, 86.5, 80.9, 77.6; IR (ATR, cm<sup>-1</sup>): 3725, 3624, 3095, 2960, 2914, 1724, 1663, 1492, 1402, 1350, 1269, 1094, 1000, 940, 831; HRMS (ESI+) Calcd for C<sub>12</sub>H<sub>9</sub>Cl<sub>4</sub>NNaO, ([M + Na]<sup>+</sup>) 345.9336, Found, 345.9331.


**(R)-4-(3-methoxyphenyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2e):** Prepared according to the representative procedure over the course of 12 h at -50 °C.; White solid (90% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 16.3 (minor), 21.8 (major) min, (90% ee) [α]<sup>25.4</sup><sub>D</sub> = +27.4 (c = 1.0, CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.31 (t, J = 7.8 Hz, 1H), 6.94 (tm, J = 1.8 Hz, 1H), 6.92 (dm, J = 7.8 Hz, 1H), 6.84 (ddm, J = 8.4, 2.4 Hz, 1H), 6.19 (dd, J = 16.8, 10.2 Hz, 1H), 5.31 (d, J = 10.8 Hz, 1H), 5.28 (d, J = 17.4 Hz, 1H), 4.90 (d, J = 8.4 Hz, 1H), 4.64 (d, J = 8.4 Hz, 1H), 3.82 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.1, 159.9, 144.4, 139.6, 129.9, 118.0, 115.3, 112.9, 111.9, 86.6, 81.1, 77.9, 55.3; IR (ATR, cm<sup>-1</sup>): 2958, 2836, 1663, 1602, 1584, 1487, 1434, 1290, 1259, 1048, 998, 949; HRMS (ESI+) Calcd for C<sub>13</sub>H<sub>12</sub>Cl<sub>3</sub>NNaO<sub>2</sub>, ([M + Na]<sup>+</sup>) 341.9831, Found, 341.9826.

**(R)-4-(m-tolyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2f):** Prepared according to the representative procedure over the course of 48 h at -60 °C.; Colorless oil (97% yield); HPLC analysis Chiralcel OB-H (Only hexane, 1.0 mL/min, 220 nm, 40 °C) 6.58 (minor), 7.78 (major) min, (91% ee); [α]<sup>22.7</sup><sub>D</sub> = +26.5 (c = 0.6, CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.27 (t, J = 7.8 Hz, 1H), 7.17 (brs, 1H), 7.14 (dm, J = 7.8 Hz, 1H), 7.11 (dm, J = 8.4 Hz, 1H), 6.19 (dd, J = 17.4, 10.8 Hz, 1H), 5.30 (d, J = 10.8 Hz, 1H), 5.26 (d, J = 16.8 Hz, 1H), 4.91 (d, J = 9.0 Hz, 1H), 4.64 (d, J = 7.8 Hz, 1H), 2.37 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.0, 142.7, 139.9, 138.5, 128.7, 128.5, 126.5, 122.8, 115.1, 86.7, 81.1, 77.9, 21.5; IR (ATR, cm<sup>-1</sup>): 3728, 2958, 2925, 1662, 1607, 1490, 1351, 1273, 1219, 998, 949, 846; HRMS (ESI+) Calcd for C<sub>13</sub>H<sub>12</sub>Cl<sub>3</sub>NNaO, ([M + Na]<sup>+</sup>) 325.9882, Found, 325.9877.

**(R)-4-(3-chlorophenyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2g):** Prepared according to the representative procedure over the course of 36 h at -40 °C.; White solid (87% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 8.59 (minor), 10.1 (major) min, (88% ee); [α]<sup>25.8</sup><sub>D</sub> = +33.2 (c = 0.8, CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)


$\delta$  7.36 (t,  $J$  = 2.4 Hz, 1H), 7.34-7.28 (m, 2H), 7.24 (dt,  $J$  = 7.8, 1.2 Hz, 1H), 6.15 (dd,  $J$  = 17.4, 10.8 Hz, 1H), 5.34 (d,  $J$  = 10.2 Hz, 1H), 5.28 (d,  $J$  = 17.4 Hz, 1H), 4.92 (d,  $J$  = 8.4 Hz, 1H), 4.61 (d,  $J$  = 8.4 Hz, 1H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  162.5, 144.7, 139.2, 134.8, 130.1, 128.0, 126.2, 124.0, 115.8, 86.5, 80.8, 77.7; IR (ATR,  $\text{cm}^{-1}$ ): 3069, 2965, 2904, 1663, 1597, 1574, 1475, 1421, 1353, 1270, 1233, 1083, 999, 949, 845, 821; HRMS (ESI $^+$ ) Calcd for  $\text{C}_{12}\text{H}_9\text{Cl}_4\text{NNaO}$ , ( $[\text{M} + \text{Na}]^+$ ) 345.9336, Found, 345.9331.

**(R)-2-(trichloromethyl)-4-(3-(trifluoromethyl)phenyl)-4-vinyl-4,5-dihydrooxazole (2h):** Prepared according to




the representative procedure over the course of 48 h at -40 °C.; White solid (86% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 7.06 (minor), 7.82 (major) min, (89% ee);  $[\alpha]^{26.7}\text{D} = +33.0$  ( $c = 0.8$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.61 (s, 1H), 7.58 (t,  $J$  = 7.2 Hz, 2H), 7.52 (t,  $J$  = 7.8 Hz, 1H), 6.18 (dd,  $J$  = 17.4, 10.8 Hz, 1H), 5.37 (d,  $J$  = 10.8 Hz, 1H), 5.29 (d,  $J$  = 16.8 Hz, 1H), 4.96 (d,  $J$  = 9.0 Hz, 1H), 4.64 (d,  $J$  = 9.0 Hz, 1H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  162.7, 143.8, 139.0, 131.2 (q,  $J$  = 32.3 Hz, 1C), 129.4 (2C), 124.7 (q,  $J$  = 4.3 Hz, 1C), 123.9 (q,  $J$  = 272.6 Hz, 1C), 122.8 (q,  $J$  = 4.3 Hz, 1C), 116.1, 86.4, 80.8, 76.8; IR (ATR,  $\text{cm}^{-1}$ ): 2932, 1665, 1332, 1269, 1228, 1169, 1130, 1075, 1001; HRMS (ESI $^+$ ) Calcd for  $\text{C}_{13}\text{H}_9\text{Cl}_3\text{F}_3\text{NNaO}$ , ( $[\text{M} + \text{Na}]^+$ ) 379.9600, Found, 379.9594.

**(R)-4-(2-methoxyphenyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2i):** Prepared according to the




representative procedure over the course of 12 h at -40 °C.; Colorless oil (90% yield).; HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 7.16 (minor), 8.86 (major) min, (67% ee);  $[\alpha]^{26.4}\text{D} = +52.1$  ( $c = 1.3$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.69 (dd,  $J$  = 7.8, 1.2 Hz, 1H), 7.30 (tm,  $J$  = 7.7 Hz, 1H), 7.00 (t,  $J$  = 7.6 Hz, 1H), 6.92 (d,  $J$  = 8.3 Hz, 1H), 6.23 (dd,  $J$  = 17.2, 10.3 Hz, 1H), 5.16 (d,  $J$  = 18.2 Hz, 1H), 5.14 (d,  $J$  = 10.3 Hz, 1H), 5.00 (d,  $J$  = 8.9 Hz, 1H), 4.61 (d,  $J$  = 8.9 Hz, 1H) 3.84 (s, 3H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  161.6, 155.4, 139.6, 131.3, 128.9, 127.3, 121.0, 114.1, 111.0, 86.9, 81.9, 76.5, 55.3; IR (ATR,  $\text{cm}^{-1}$ ): 3012, 2971, 2944, 2841, 1672, 1583, 1488, 1463, 1403, 1353, 1284, 1242, 1182, 1159, 1119, 1027, 996, 937, 845, 821; HRMS (ESI $^+$ )  $\text{C}_{13}\text{H}_{12}\text{Cl}_3\text{NNaO}_2$ , ( $[\text{M} + \text{Na}]^+$ ) 341.9831, Found, 341.9826.

**(R)-4-(2-fluorophenyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2k):** Prepared according to the




representative procedure over the course of 12 h at -20 °C.; Colorless oil (87% yield).; HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 5.17 (minor), 5.53 (major) min, (90% ee);  $[\alpha]^{26.8}\text{D} = +65.1$  ( $c = 0.9$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.70 (dt,  $J$  = 7.7, 1.7 Hz, 1H), 7.34-7.29 (m, 1H), 7.18 (tm,  $J$  = 7.3 Hz, 1H), 7.09 (dd,  $J$  = 11.0, 8.3 Hz, 1H), 6.17 (dd,  $J$  = 17.2, 10.7 Hz, 1H), 5.23 (d,  $J$  = 10.7 Hz, 1H), 5.20 (d,  $J$  = 17.2 Hz, 1H), 5.02 (dd,  $J$  = 8.9, 3.1 Hz, 1H), 4.66 (dd,  $J$  = 8.9, 2.1 Hz, 1H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  162.3, 159.3 (d,  $J$  = 246 Hz, 1C), 138.6, 130.1 (d,  $J$  = 14.5 Hz, 1C), 129.6 (d,  $J$  = 8.7 Hz, 1C), 127.9 (d,  $J$  = 4.3 Hz, 1C), 124.5, 115.8 (d,  $J$  = 21.7 Hz, 1C), 115.2, 86.6, 81.4, 75.8; IR (ATR,  $\text{cm}^{-1}$ ): 2959, 2903, 1666, 1488, 1455, 1405, 1356, 1283, 1264, 1219, 998, 943; HRMS (ESI $^+$ ) Calcd for  $\text{C}_{12}\text{H}_9\text{Cl}_3\text{FNNaO}$ , ( $[\text{M} + \text{Na}]^+$ ) 329.9631, Found, 329.9626.

**(R)-4-(naphthalen-2-yl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2l):** Prepared according to the




representative procedure over the course of 12 h at -60 °C.; White solid (85% yield); HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.5:0.5, 1.0 mL/min, 220 nm, 40 °C) 10.5 (minor), 11.0 (major) min, (86% ee);  $[\alpha]^{23.4}_D = -3.6$  ( $c = 1.3$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.87-7.82 (m, 4H), 7.51-7.48 (m, 2H), 7.41 (dd,  $J = 8.3, 1.7$  Hz, 1H), 6.28 (dd,  $J = 17.4, 10.5$  Hz, 1H), 5.35 (d,  $J = 10.3$  Hz, 1H), 5.31 (d,  $J = 17.2$  Hz, 1H), 4.99 (d,  $J = 8.6$  Hz, 1H), 4.75 (d,  $J = 8.6$  Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.3, 139.9, 139.7, 133.2, 132.7, 128.8, 128.2, 127.6, 126.5, 126.3, 124.7, 123.8, 115.6, 86.7, 81.0, 78.2; IR (ATR, cm<sup>-1</sup>): 3726, 3344, 3058, 3018, 2921, 1661, 1635, 1601, 1506, 1470, 1405, 1354, 1269, 1221, 1184, 1129, 1080, 998, 938, 901, 845, 820; HRMS (ESI+) Calcd for C<sub>16</sub>H<sub>12</sub>Cl<sub>3</sub>NNaO, ([M + Na]<sup>+</sup>) 361.9882, Found, 361.9876.

**(R)-4-(phenylethynyl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2m):** Prepared according to the



representative procedure over the course of 48 h at -40 °C.; Colorless oil (55% yield).; HPLC analysis Chiralcel OD-3 (Hexane only, 1.0 mL/min, 220 nm, 40 °C) 21.88 (major), 25.08 (minor) min, (62% ee);  $[\alpha]^{23.9}_D = -31.9$  ( $c = 0.5$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.48 (dd,  $J = 7.8$  Hz, 1.8 Hz, 2H), 7.36-7.30 (m, 3H), 5.99 (dd,  $J = 16.8, 10.3$  Hz, 1H), 5.70 (d,  $J = 16.8$  Hz, 1H), 5.39 (d,  $J = 10.2$  Hz, 1H), 4.84 (d,  $J = 8.4$  Hz, 1H), 4.64 (d,  $J = 7.8$  Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 163.7, 136.5, 131.8, 128.9, 128.3, 122.0, 117.4, 88.0, 86.1, 81.6, 70.4, 29.7; IR (ATR, cm<sup>-1</sup>): 2956, 2925, 2852, 1727, 1657, 1600, 1490, 1407, 1259, 998, 849; HRMS (ESI+) Calcd for C<sub>14</sub>H<sub>10</sub>Cl<sub>3</sub>NNaO, ([M + Na]<sup>+</sup>) 335.9726, Found, 335.9720.


**(R)-4-(thiophen-3-yl)-2-(trichloromethyl)-4-vinyl-4,5-dihydrooxazole (2n):** Prepared according to the



representative procedure over the course of 8 h at -60 °C.; Colorless oil (95% yield).; HPLC analysis Chiralcel OD-3 (Hex:IPA = 99.8:0.2, 1.0 mL/min, 220 nm, 40 °C) 10.36 (minor), 10.83 (major) min, (91% ee);  $[\alpha]^{26.1}_D = -20.8$  ( $c = 0.9$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.36 (dd,  $J = 5.2, 3.1$  Hz, 1H), 7.23 (dd,  $J = 3.1, 1.4$  Hz, 1H), 7.01 (dd,  $J = 5.2, 1.4$  Hz, 1H), 6.23 (dd,  $J = 17.2, 10.7$  Hz, 1H), 5.33 (d,  $J = 10.7$  Hz, 1H), 5.30 (d,  $J = 17.2$  Hz, 1H), 4.80 (d,  $J = 8.6$  Hz, 1H), 4.68 (d,  $J = 8.6$  Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.4, 143.4, 139.0, 126.9, 125.5, 121.6, 115.7, 86.6, 81.1, 75.8; IR (ATR, cm<sup>-1</sup>): 3108, 2962, 2925, 2854, 1740, 1661, 1470, 1409, 1351, 1267, 1219, 998, 950, 849; HRMS (ESI+) Calcd for C<sub>10</sub>H<sub>8</sub>Cl<sub>3</sub>NNaOS, ([M + Na]<sup>+</sup>) 317.9290, Found, 317.9284.

## 5. Additional Screenings


### 5-1. Screening of solvents



**Table S1**


entry	solvent	yield (%)	ee (%)	note
1	CH <sub>2</sub> Cl <sub>2</sub>	96	75	
2	CHCl <sub>3</sub>	96	89	5 mol% of catalyst was used
3	toluene	94	70	
4	THF	4	1	
5	Et <sub>2</sub> O	20	14	
6	MeCN	8	-8	

### 5-2. Screening of catalyst substituent G




**Table S2.**

<i>entry</i>	<i>catalyst</i>	<b>G</b>	<i>yield (%)</i>	<i>%ee</i>	<i>note</i>
1	( <i>R</i> )- <b>3a</b>	9-Anthryl	92	27	
2	( <i>R</i> )- <b>3e</b>	Ph	90	-2	
3	( <i>R</i> )- <b>3f</b>	4-PhC <sub>6</sub> H <sub>4</sub>	85	-5	
4	( <i>R</i> )- <b>3g</b>	3,5-( <i>t</i> Bu) <sub>2</sub> C <sub>6</sub> H <sub>3</sub>	79	6	1 h
5	( <i>R</i> )- <b>3h</b>	2,4,6-( <i>i</i> Pr) <sub>3</sub> C <sub>6</sub> H <sub>2</sub>	52	6	24 h
6	( <i>R</i> )- <b>3i</b>	SiPh <sub>3</sub>	35	5	24 h
7	( <i>R</i> )- <b>3j</b>	9-Phenanthryl	90	17	
8	( <i>R</i> )- <b>3k</b>	10-Mesityl-9-Anthryl	95	-8	
9	( <i>R</i> )- <b>3l</b>	9-Anthryl	90	22	1 h
10	( <i>R</i> )- <b>3m</b>	9-Anthryl	trace	n.d.	72 h

**5-3. The use of (*Z*)-1a as a substrate**

## 6. Derivatization of Product




**(R)-2,2,2-trichloro-N-(1-hydroxy-2-phenylbut-3-en-2-yl)acetamide (5):** To a solution of **2a** (29 mg, 0.1 mmol, 95% ee) in EtOH (1 mL) solution was added  $\text{NH}_4\text{Cl}$  (1 ml) at room temperature. The reaction mixture was stirred for 48 h, then  $\text{H}_2\text{O}$  was added and extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated after filtration. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 10/1) to give the **5** (29 mg, 95% yield) as a white solid.

**5** HPLC analysis Chiralpak IA-3 (Hex:IPA = 98:2, 1.0 mL/min, 220 nm,  $40^\circ\text{C}$ ) 24.1 (minor), 26.2 (major) min, (96% ee);  $[\alpha]^{24.8}_D = -22.2$  ( $c = 1.2, \text{CH}_2\text{Cl}_2$ );  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.49 (brs, 1H), 7.42-7.32 (m, 5H), 6.37 (dd,  $J = 17.6, 10.7$  Hz, 1H), 5.52 (d,  $J = 10.7$  Hz, 1H), 5.36 (d,  $J = 17.5$  Hz, 1H), 3.99 (d,  $J = 12.0$  Hz, 1H), 3.91 (d,  $J = 12.0$  Hz, 1H), 2.51 (brs, 1H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  160.8, 139.1, 136.0, 128.9, 128.2, 125.9, 117.3, 93.0, 68.5, 65.8; IR (ATR,  $\text{cm}^{-1}$ ): 3387, 2927, 2860, 2371, 2346, 2320, 1720, 1499, 1248, 1044; HRMS (ESI+) Calcd for  $\text{C}_{12}\text{H}_{12}\text{Cl}_3\text{NNaO}_2$ , ( $[\text{M} + \text{Na}]^+$ ) 329.9831, Found, 329.9826.


**(R)-4-phenyl-4-vinyloxazolidin-2-one (6):** To a solution of **5** (29 mg, 0.1 mmol) in EtOH (1mL) was added  $\text{LiOH}\cdot\text{H}_2\text{O}$  (21 mg, 0.5 mmol, 5 eq.) at room temperature. The reaction mixture was stirred for 1 h, then  $\text{H}_2\text{O}$  was added and extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated after filtration. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 10/1) to give the **6** (16 mg, 90% yield) as a white solid.

**6** HPLC analysis Chiralcel OD-3 (Hex:IPA = 95:5, 1.0 mL/min, 220 nm,  $40^\circ\text{C}$ ) 21.6 (major), 23.7 (minor) min, (96% ee);  $[\alpha]^{24.7}_D = +24.7$  ( $c = 0.25, \text{CHCl}_3$ );  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.42-7.32 (m, 5H), 6.71 (brs, 1H), 6.21 (dd,  $J = 17.2, 10.3$  Hz, 1H), 5.36 (d,  $J = 10.3$  Hz, 1H), 5.32 (d,  $J = 17.2$  Hz, 1H), 4.56 (d,  $J = 8.6$  Hz, 1H), 4.48 (d,  $J = 8.6$  Hz, 1H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  159.2, 141.1, 139.2, 129.0, 128.2, 125.3, 115.8, 76.3, 64.6; IR (ATR,  $\text{cm}^{-1}$ ): 3260, 2959, 2927, 2856, 1752, 1449, 1387, 1276, 1125, 1037, 938; HRMS (ESI+) Calcd for  $\text{C}_{11}\text{H}_{11}\text{NNaO}_2$ , ( $[\text{M} + \text{Na}]^+$ ) 212.0687, Found, 212.0682.

**(R)-2-amino-2-phenylbut-3-en-1-ol (7):** To a solution of **5** (29 mg, 0.1 mmol) in EtOH (1 mL) and H<sub>2</sub>O (0.3 mL) was added LiOH-H<sub>2</sub>O (21 mg, 0.5 mmol, 5 eq.) at room temperature. The reaction mixture was stirred at 100 °C for 10 h. Then H<sub>2</sub>O was added and extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration. The residual crude was pure **7** as a white solid.




**tert-butyl (R)-(1-hydroxy-2-phenylbut-3-en-2-yl)carbamate (8):** To a solution of **7** (16mg, 0.1 mmol) in saturated NaHCO<sub>3</sub> solution (1 mL) and THF (1 mL) was added Boc<sub>2</sub>O (0.33 g, 1.5 mmol, 3 equiv) at room temperature. The reaction mixture was stirred for overnight. Then H<sub>2</sub>O was added and extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 2/1) to give the **8** (23.7 mg, 90% yield) as a white solid.



## 7. Mechanistic Study

### 7-1. Deuterium experiment

#### 7-1-1. Preparation of deuterated material (*S*)-*d*-1a




**ethyl (*E*)-4-((tert-butyldimethylsilyl)oxy)-3-phenylbut-2-enoate (S10):** A 30 mL round bottom flask was charged with **S9** (1.5 g, 6.3 mmol, 1.0 eq), Ethyl (triphenylphosphoranylidene)acetate (3.3 g, 9.5 mmol), and ClCH<sub>2</sub>CH<sub>2</sub>Cl (6.3 mL). The mixture was allowed to warm to 100 °C for 12 h. The residual crude was directly purified by flash column chromatography on silica gel (Hexane/EtOAc = 40/1 to 20/1) to provide **S10** (1.48 g, 73% yield, 4.6 mmol) as a colorless oil.


**EtO<sub>2</sub>C-CH=CH-OTBS (S10):** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.36–7.31 (m, 3H), 7.17–7.16 (m, 2H), 6.20 (s, 1H), 4.33 (s, 2H), 4.00 (q, *J* = 7.2 Hz, 3H), 1.07 (t, *J* = 7.2 Hz, 3H), 0.95 (s, 9H), 0.11 (s, 6H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 166.3, 157.6, 137.5, 127.9, 127.4, 127.3, 115.2, 66.8, 59.8, 25.9, 18.4, 13.9, -5.5; IR (ATR, cm<sup>-1</sup>): 2955, 2929, 2857, 1725, 1655, 1471, 1444, 1363, 1333, 1255, 1220, 1154, 1130, 1045, 837, 697; HRMS (ESI+) Calcd for C<sub>18</sub>H<sub>28</sub>NaO<sub>3</sub>Si, ([M + Na]<sup>+</sup>) 343.1705, Found, 343.1700.

**(*E*)-4-((tert-butyldimethylsilyl)oxy)-3-phenylbut-2-enoic acid (S12):** A 20 mL round bottom flask was charged with **S10** (320 mg, 1.0 mmol, 1.0 eq), LiOH (84 mg, 2.0 mmol, 2.0 eq), THF (8 mL), H<sub>2</sub>O (1 mL) and MeOH (1

mL). The mixture was allowed to warm to 60 °C for 3 h. Then the solvent was removed under reduced pressure and H<sub>2</sub>O and Et<sub>2</sub>O were added. Organic layer was extracted with H<sub>2</sub>O. The combined aqueous extracts were washed with Et<sub>2</sub>O, then acidified with 1 M HCl aq. (pH= ~4) and extract with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration to give the crude product **S6**. The crude product **S11** was used next step without purification. To an ice bath cooled solution of **S11** in THF (10 mL) was added imidazole (150 mg, 2.2 mmol, 2.2 eq) and TBSCl (332 mg, 2.2 mmol, 2.2 eq). The mixture was stirred at 0 °C for 1 h. Then the reaction mixture was added K<sub>2</sub>CO<sub>3</sub> (276 mg, 2.0 mmol, 2.0 eq) and MeOH (5 mL). The mixture was stirred at 0 °C for 30 min (monitored by TLC). Then the solvent was removed under reduced pressure and added H<sub>2</sub>O and EtOAc (~15 mL). The combined layer was acidified with 1 M HCl aq. (pH= ~4) and extract with EtOAc (10 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration to give the crude product **S12** (249 mg, 85% yield, 0.85 mmol) as a white solid. The crude product **S12** was used next step without purification.




**(E)-4-((tert-butyldimethylsilyl)oxy)-3-phenylbut-2-en-1,1-d<sub>2</sub>-1-ol (S13):** To an ice bath cooled solution of **S12** (205 mg, 0.7 mmol, 1.0 eq), NEt<sub>3</sub> (107 μL, 0.77 mmol, 1.1 eq) in THF (7 mL) was added methyl carbonochloridate (59 μL, 0.77 mmol, 1.1 eq). The mixture was stirred at 0 °C for 10 min. Then NaBD<sub>4</sub> (117 mg, 2.8 mmol, 4.0 eq) and D<sub>2</sub>O (350 μL) were added to the reaction mixture. The mixture was stirred at 0 °C for 10 min. Then the reaction mixture was quenched with NH<sub>4</sub>Cl sat. and extract with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration to give the crude product. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 20/1 to 10/1) to give the product **S13** (182 mg, 0.65 mmol, 93% yield, <95% D) as a colorless oil.




**(E)-4-((tert-butyldimethylsilyl)oxy)-3-phenylbut-2-enal-1-d (S14):** To an acetone bath cooled solution of (COCl)<sub>2</sub> (61 μL, 0.72 mmol, 1.1 eq) in CH<sub>2</sub>Cl<sub>2</sub> (7 mL) was added DMSO (92 μL, 1.3 mmol, 2.0 eq) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) dropwise. After 10 min, **S13** (182 mg, 0.65 mmol, 1.0 eq) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added dropwise. After 15 min, NEt<sub>3</sub> (460 μL, 3.3 mmol, 5.0 eq) was added to the reaction mixture. After 15 min, the mixture was gradually warmed up to room temperature. Then the reaction mixture was quenched with H<sub>2</sub>O. The combined CH<sub>2</sub>Cl<sub>2</sub> solution were washed with NH<sub>4</sub>Cl sat. and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration to give the crude product. The residual


crude was purified by silica gel column chromatography (Hexane/EtOAc = 20/1) to give the product **S14** (95 mg, 0.39 mmol, 54% yield, <98% D) as a yellow oil.



**(S, E)-4-((tert-butyldimethylsilyl)oxy)-3-phenylbut-2-en-1-d-1-ol (S15):** To a solution of (*R*)-Alpine-Borane (1.1 mL, 0.54 mmol, 1.2 eq, 0.5 M in THF solution) in THF (2.8 mL) was added **S14** (125 mg, 0.45 mmol, 1.0 eq) dropwise at -78 °C. The resulting reaction mixture was stirred for 4 h at the same temperature, then gradually warmed up to room temperature and stirred for 12 h. To the resulting reaction mixture was added acetaldehyde (126 μL, 2.3 mmol, 5.0 eq) at 0 °C. After stirring for 15 min, NaOH aq. (200 μL) and H<sub>2</sub>O<sub>2</sub> (126 μL, 2.3 mmol, 5.0 eq) were added. After stirring for 30 min, H<sub>2</sub>O was added to the reaction mixture and extract with Et<sub>2</sub>O. The combined Et<sub>2</sub>O extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated after filtration to give the crude product. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 20/1 to 10/1) to give the product **S15** (95 mg, 0.34 mmol, 75% yield) as a colorless oil.




**(S, E)-2-phenylbut-2-ene-4-d-1,4-diol ((S)-d-S6):** To an ice bath cooled solution of **S15** (84 mg, 0.3 mmol) in THF (1.5 mL) was added TBAF (450 μL, 0.45 mmol, 1.5 eq, 1 M in THF solution). The mixture was stirred at 0 °C for 1 h. Then the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography (Hexane/EtOAc = 4/1 to EtOAc only) to give the product (*S*)-*d*-**S6** (48.6 mg, 0.29 mmol, 98% yield) as a colorless oil.




**(E)-2-phenylbut-2-ene-1,4-diyl-4-d bis(2,2,2-trichloroacetimidate) ((S)-d-1a):** To a solution of (*S*)-*d*-**S6** (41 g, 0.25 mmol, 1.0 eq) in CH<sub>2</sub>Cl<sub>2</sub> (1.3 mL) was added MS4 Å and DBU (8 μL, 0.05 mmol, 0.2 eq). The reaction mixture was cooled to 0 °C, then trichloroacetonitrile (63 μL, 0.63 mmol, 2.5 eq) was added and stirred for 2 h at the same

temperature. Then the reaction mixture was warmed to room temperature and concentrated. The residual crude was purified by flash column chromatography (Hexane/EtOAc = 20/1) to provide (*S*)-*d*-**1a** (91 mg, 0.2 mmol, 80% yield) as a colorless oil.




#### 7-1-2. Reaction of chiral deuterated substrate




To a CHCl<sub>3</sub> (0.5 mL) solution of (*S*)-*d*-**1a** (24.3 mg, 0.05 mmol, 1.0 equiv.) and MS4A (25 mg) was added (*R*)-**3d** (5 mg, 0.05 mmol, 10 mol%) at -60 °C for 48 h. The reaction mixture was quenched with NEt<sub>3</sub> (10 μL) and directly purified by flash silica gel column chromatography (Hexane/EtOAc = 30/1 as eluent) to give (*Z*)-*d*-**2a** (14.6 mg, 90%).

**(*R,Z*)-4-phenyl-2-(trichloromethyl)-4-(vinyl-2-*d*)-4,5-dihydrooxazole ((*Z*)-*d*-**2a**):** HPLC analysis Chiralcel OD-




7-1.3. Determination of absolute configuration of allylic alcohol **S10** by Mosher ester analysis<sup>3</sup>.

(R)- and (S)- MTPA esterification




Mosher's conformational model for MTPA ester (The case of (**S**)-alcohol is shown)

(R)-MTPA ester




(S)-MTPA ester



|| MTPA ester would be expected to exist in 60° rotation about the allylic C-O bond

<sup>1</sup>H and <sup>2</sup>H NMR Chemical Shifts of MTPA Adducts

entry	compound	H δ (ppm)	D δ (ppm)
1	(R)-MTPA ester	4.725	4.789
2	(S)-MTPA ester	4.757	4.754
		Δ <sub>R-S</sub> = -0.032	Δ <sub>R-S</sub> = +0.035



H: Δ<sub>(R)-ester - (S)-ester</sub> = < 0,


D: Δ<sub>(R)-ester - (S)-ester</sub> = > 0

Absolute configuration is decided to **S**-isomer.


|| This configuration of the alcohol is in agreement with the absolute configuration derived from the expected stereoselectivity of the Alpine-Brane reduction<sup>4</sup>.

## 7-2. Mechanistic study for phosphorimidate **B**

7-2-1.  $^{31}\text{P}$  NMR monitoring of the reaction of **1a** catalyzed by **3c**



In  $\text{CDCl}_3$  (0.6 mL), at  $-40^\circ\text{C}$ , the reaction using **1a** (27 mg, 0.06 mmol, 1.0 equiv.) and **(R)-3c** (9.3 mg, 0.001 mmol), was monitored for 4 h by  $^{31}\text{P}$  NMR. In this reaction, the formation of a new peak **B** was detected.



*Figure 1. NMR monitoring of reaction ( $^{31}\text{P}$  NMR)*

We also measured the  $^{31}\text{P}$  NMR spectrum without  $^1\text{H}$  decoupling in the presence of  $\text{PO}(\text{OMe})_3$  as an internal standard. As a result, formation of a new peak (dd,  $J = 16.4, 6.6 \text{ Hz}$ ) which couples to two neighboring protons was observed. This result indicates that the  $\text{S}_{\text{N}}2$  reaction of catalyst **3c** with **1a** at the terminal allylic position of the far side from Ph group proceeded.





Figure 2.  $^{31}\text{P}$  NMR spectrum w/o  $^1\text{H}$  decoupling.


## 7-2-2. Preparation of allyl phosphorimidate




To determine the structure of phosphorimidate **B**, we prepared allyl phosphorimidate from the reaction of catalyst *(R)*-**3c** and allyltrichloroacetimidate **S16**.: **S16** (5 mg, 0.025 mmol, 2.5 equiv.) and dry  $\text{CDCl}_3$  (0.6 mL) were added to an NMR tube, and then *(R)*-**3c** (9.3 mg, 0.01 mmol, 1.0 equiv.) was added at room temperature. The mixture was shaken for about 30 s and then was analyzed by  $^1\text{H}$  and/or  $^{31}\text{P}$  NMR. The result of the  $^1\text{H}$  and/or  $^{31}\text{P}$  NMR is consistent with the allyl phosphorimidate **S19**. Therefore, it was found that the phosphoryl oxygen attacks at the carbon having the leaving group to generate phosphorimidate in the  $\text{S}_{\text{N}}2$  reaction process.

**Figure 3.** Comparing NMR spectrum of Adduct **S16** with allyl phosphorimidate **S19** and **S20**.


$^1\text{H}$  NMR Spectra




$^{31}\text{P}$  NMR Spectra (w/o  $^1\text{H}$  decoupling)



7-2-3. Procedure for the preparation of allyl phosphorimidate



**2,3,4,5,6-pentafluorobenzenesulfonyl azide (S17):** To an ice bath cooled solution of sodium azide (39 mg, 0.6 mmol, 1.2 eq) in acetone (1 mL) and H<sub>2</sub>O (1 mL) was added pentafluorobenzenesulfonyl chloride (74 μL, 0.5 mmol, 1.0 eq) dropwise. After the mixture was stirred at 0 °C for 12 h, sat. NaHCO<sub>3</sub> (1 mL) was added and acetone was removed under reduced pressure. Then the resulting aqueous phase was extracted with toluene. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 50/1) to give the product **S17** (89 mg, 0.33 mmol, 66% yield) as a colorless oil.




<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 145.5 (dm, *J* = 266 Hz, 1C), 144.9 (dm, *J* = 263 Hz, 2C), 138.1 (dm, *J* = 261 Hz, 2C), 115.1 (m, 1C); <sup>19</sup>F NMR (151 MHz, CDCl<sub>3</sub>): δ -134.0 (m, 2F), -141.2 (m, 1F), -156.8 (m, 2F); IR(neat, cm<sup>-1</sup>): 2144, 1644, 1501, 1398, 1306, 1178, 1103, 994.

**S17** was unstable under the analysis conditions of HRMS

**(6s,11bR)-4-(allyloxy)-2,6-di(anthracen-9-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine (S18):** In a flame


dried flask under N<sub>2</sub>, **S4** (319 mg, 0.5 mmol, 1.0 equiv) and NEt<sub>3</sub> (1.2 mL, 8.5 mmol, 17 equiv) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL, 0.05 M). The mixture was cooled to -78 °C and added PBr<sub>3</sub> (57 μL, 0.6 mmol, 1.2 equiv) dropwise. The mixture was gradually warmed up to room temperature and allyl alcohol (102 μL, 1.5 mmol, 3.0 equiv) was added. After the reaction mixture was stirred for 12 h, solvent was removed under reduced pressure. Then the residual crude was purified by flash column chromatography on silica gel (Hexane/Acetone = 20/1), to give the product **S18** (200 mg, 0.28 mmol, 55% yield) as a white solid.



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.47 (s, 2H), 8.06-7.17 (m, 26H), 4.56 (m, 1H), 4.09 (d, *J* =

10.7 Hz, 1H), 3.78 (d,  $J$  = 17.2 Hz, 1H), 2.82 (ddt,  $J$  = 17.0, 10.3, 4.8 Hz, 1H), 2.72 (tdm,  $J$  = 14.4, 5.2 Hz, 1H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  147.55, 147.06, 133.11, 132.95, 132.87, 132.84, 132.73, 131.85, 131.44, 131.34, 131.19, 131.09, 131.00, 130.93, 130.86, 130.73, 130.66, 130.43, 128.54, 128.37, 128.24, 128.12, 128.10, 128.07, 127.69, 127.42, 127.36, 127.07, 127.05, 126.98, 126.93, 126.86, 126.49, 126.37, 125.80, 125.75, 125.52, 125.42, 125.39, 125.31, 125.20, 125.09, 125.02, 124.95, 124.79, 123.73, 115.33, 63.91, 63.75, 22.86, one carbon was not found probably due to overlapping;  $^{31}\text{P}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  153.8; IR(neat,  $\text{cm}^{-1}$ ): 3052, 1444, 1402, 1233, 1085, 1014, 937, 866, 795; HRMS(ESI+): Calcd for  $\text{C}_{51}\text{H}_{33}\text{NaO}_3\text{P}$ ,  $[\text{M}+\text{Na}]^+$ , 747.2065; found, 747.2060.


**N-((2*r*,11*b*R)-4-(allyloxy)-2,6-di(antracen-9-yl)-4*I*5-dinaphtho[2,1-*d*:1',2'-*f*][1,3,2]dioxaphosphhepin-4-ylidene)-2,3,4,5,6-pentafluorobenzenesulfonamide (S19):** S18 (7.2 mg, 0.01 mmol, 1.0 equiv.) and dry  $\text{CDCl}_3$  (0.6 mL)



were added to an NMR tube, and then S17 (4.1 mg, 0.015 mmol, 1.5 equiv.) was added at room temperature. The mixture was left for 2 days and then was analyzed. S19 was unstable on the purification conditions.

$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.53 (s, 1H), 8.50 (s, 1H), 8.17 (s, 2H), 8.08-7.20 (m, 24H), 4.63 (m, 1H), 4.30 (dm,  $J$  = 10.3 Hz, 1H), 4.21 (ddm,  $J$  = 17.5, 1.4 Hz, 1H), 3.71 (m, 1H), 3.05 (dddm,  $J$  = 18.2, 10.2, 6.2 Hz, 1H);  $^{31}\text{P}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.43; IR(neat,  $\text{cm}^{-1}$ ): 3053, 2145, 1494, 1445, 1402, 1329, 1253, 1200, 1164, 1097, 1034, 988, 915, 795, 733.; HRMS(ESI+): Calcd for  $\text{C}_{57}\text{H}_{33}\text{F}_5\text{NNaO}_5\text{PS}$ ,  $[\text{M}+\text{Na}]^+$ , 992.1635; found, 992.1629.


**N-allyl-N-((2*r*,11*b*R)-2,6-di(antracen-9-yl)-4-oxidodinaphtho[2,1-*d*:1',2'-*f*][1,3,2]dioxaphosphhepin-4-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide (S20):** To a solution of S4 (64 mg, 0.1 mmol, 1.0 equiv) and  $\text{NEt}_3$  (70  $\mu\text{L}$ , 0.5 mmol, 5.0 equiv) in  $\text{CH}_2\text{Cl}_2$  (1.0 mL, 0.1 M) was added  $\text{PBr}_3$  (11.4  $\mu\text{L}$ , 0.12 mmol, 1.2 equiv) at 0 °C. After stirring for 30 min, *N*-allyl-pentafluorobenzenesulfonamide (52 mg, 0.2 mmol, 2.0 equiv) was added. After 1 hour, the mixture was filtered through a pad of silica with  $\text{CH}_2\text{Cl}_2$  and the solvent was removed in vacuo. Then the resulting material was dissolved in  $\text{CH}_2\text{Cl}_2$  (1.0 mL, 0.1 M) and treated with *m*CPBA (49 mg, 0.2 mmol, 2.0 eq). After 15 min, the crude mixture was directly purified by flash column chromatography on silica gel (Hexane/EtOAc = 20/1) to give the product S20 (9.7 mg, 0.1 mmol, 10% yield) as a white solid.



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.56 (s, 1H), 8.51 (s, 1H), 8.20-7.16 (m, 26H), 4.22 (dm,  $J$  = 16.8 Hz, 1H), 3.89 (d,  $J$  = 10.0 Hz, 1H), 3.73 (m, 1H), 3.20 (m, 1H), 3.13 (td,  $J$  = 15.6, 6.2 Hz, 1H);  $^{31}\text{P}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  -1.79; IR(neat,  $\text{cm}^{-1}$ ): 3013, 1520, 1497, 1385, 1309, 1228, 1177, 1100, 992, 956, 905, 794; HRMS(ESI+): Calcd for  $\text{C}_{57}\text{H}_{33}\text{F}_5\text{NNaO}_5\text{PS}$ ,  $[\text{M}+\text{Na}]^+$ , 992.1635; found, 992.1629.


#### 7-2-4. Control experiment using substrate **1a'**

In order to further investigate whether phosphorimidate **B** is a reactive intermediate or not, we employed substrate **1a'**, which does not undergo the cyclization reaction but transforms into phosphorimidate **B'** under catalytic conditions. The formation rate of **B'** was monitored by  $^{31}\text{P}$  and  $^1\text{H}$  NMR measurement and compared with that of the actual catalytic reaction. (*R*)-**3c** was partially transformed into phosphorimidate **B'** and still remained in the (*R*)-**3c** / **B'** ratio = 2.4:1 even after 6 h at  $-40^\circ\text{C}$ , despite use of a larger amount of (*R*)-**3c** (25 mol%) than that in the optimized reaction conditions (10 mol%). In contrast, in the actual reaction of **1a** catalyzed by (*R*)-**3c** (10 mol%) at  $-40^\circ\text{C}$ , most of substrate **1a** was consumed to afford corresponding product **2a** in 88% yield after 2.5 h. Based on the result obtained in the actual reaction (2.5 h, 88% yield), most of (*R*)-**3c** should be transformed into phosphorimidate **B'**, which would accumulate during the NMR monitoring of the reaction of **1a'** catalysed by (*R*)-**3c** for 6 h, because further cyclization, i.e., the consumption of **B'**, does not occur in this case. Consequently, the formation of **B'** is much slower than that of **2a** in the actual reaction. These results also suggest that phosphorimidate **B** is not the active intermediate in the present reaction.



**Figure 4.**  $^{31}\text{P}$  NMR spectrum of **1a'** under the influence of (*R*)-**3c** at  $-40^\circ\text{C}$  after 6 h: Monitoring the formation of phosphorimidate **B'**.

### 7-3. Non linear effect (NLE) experiments




To a  $\text{CHCl}_3$  (0.5 mL) solution of **1a** (45 mg, 0.05 mmol, 1.0 equiv) and MS4A (25 mg) was added **3d** (5 mg, 0.005 mmol, 10 mol%, mixtures of two enantiomers determined by weight) at  $-60\text{ }^\circ\text{C}$  and stirred for 48 h. The reaction mixture was quenched with  $\text{NEt}_3$  (10  $\mu\text{L}$ ) and directly purified by flash silica gel column chromatography to give **2a**. The enantiomeric excess of **2a** was determined by chiral stationary phase HPLC analysis.

As a result, linear relationship between ee of **3d** (%) and ee of **2a** (%) was observed and hence this result strongly suggests that one catalyst molecule is involved in the reaction.


**Table S3**

entry	ee of <b>3d</b> (%)	ee of <b>2a</b>	Calculated ee
1	0	-5	0
2	20	24	18.8
3	40	44	37.6
4	60	60	56.4
5	80	71	75.2
6	100	94	94
7	-100	-91	-91

**Figure 5**



### 7-4. Effect of additive




**Table S4**

entry	<b>LG</b>	time	Additive	yield	ee	note
1		18 h	None	90	60	
2		24 h	$\text{Cl}_3\text{CCONH}_2$	92	58	
3		24 h	None	92	83	5 mol% of catalyst
4		24 h	$\text{F}_3\text{CCONH}_2$	92	78	5 mol% of catalyst

## 7-5. Synthesis of the other substrate


7-5-1. Preparation of substrate having a different leaving group.




entry	<b>LG</b>	Base	Electrophile	<b>Product 9</b>	Yield (3 steps from S21)
1		DBU (2.0 eq)	CF <sub>3</sub> CN <sup>a</sup> (5.0 eq)	<b>9a</b>	40% yield
2		DBU (2.0 eq) DMAP (0.3 eq)	Cl-C(=O)N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> (1.4 eq)	<b>9b</b>	40% yield
3		NaH (1.2 eq)	Cl-C(=O)-C <sub>6</sub> H <sub>3</sub> (NO <sub>2</sub> ) <sub>2</sub> (1.2 eq)	<b>9c</b>	75% yield

<sup>a</sup> *in situ* generated.


**(E)-4-((tert-butyldimethylsilyl)oxy)-3-phenylbut-2-en-1-ol (S20)** : colorless oil; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ



**(E)-3-phenyl-4-(2,2,2-trichloro-1-iminoethoxy)but-2-en-1-yl 2,2,2-trifluoroacetimidate (9a)** : 40% yield (3 steps); yellow oil; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.34 (bs, 1H), 8.14 (bs, 1H), 7.39-7.27 (m, 5H), 6.15 (t, J = 6.9 Hz, 1H), 5.06 (s, 2H), 4.76 (d, J = 6.9 Hz, 2H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.3, 157.6 (q, 38 Hz, 1C), 141.2, 135.9, 128.5, 128.4, 128.3, 122.5, 115.5 (q, 280 Hz, 1C), 91.2, 71.6, 64.7; <sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -74.3 (s); IR (ATR, cm<sup>-1</sup>): 3342, 3060, 2933, 1685, 1663, 1496, 1444, 1300, 1197, 1165, 1071, 1013, 988, 827, 796, 701, 648; HRMS (ESI+) Calcd for C<sub>14</sub>H<sub>12</sub>Cl<sub>3</sub>F<sub>3</sub>N<sub>2</sub>NaO<sub>2</sub>, ([M + Na]<sup>+</sup>) 424.9814, Found, 424.9809.




**(E)-3-phenyl-4-(2,2,2-trichloro-1-iminoethoxy)but-2-en-1-yl-2,2-trifluoro-N-phenethylacetimidate (9b) :**



40% yield (3 steps); yellow oil;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.39 (bs, 1H), 7.42-7.17 (m, 10H), 6.11 (t,  $J = 6.9$  Hz, 1H), 5.06 (s, 2H), 4.62 (d,  $J = 6.9$  Hz, 2H), 3.73 (tm,  $J = 7.4$  Hz, 2H), 2.84 (t,  $J = 7.2$  Hz, 2H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  162.3, 145.8 (q, 35 Hz, 1C), 140.1, 139.6, 136.3, 128.9, 128.45, 128.39, 128.27, 128.1, 126.2, 124.0, 116.0 (q, 286 Hz, 1C), 91.2,


71.9, 63.7, 48.8, 37.8;  $^{19}\text{F}$  NMR (565 MHz,  $\text{CDCl}_3$ )  $\delta$  -66.9 (s); IR (ATR,  $\text{cm}^{-1}$ ): 3344, 3063, 3027, 2947, 1703, 1664, 1496, 1455, 1307, 1195, 1149, 1062, 779, 700; HRMS (ESI $^+$ ) Calcd for  $\text{C}_{22}\text{H}_{20}\text{Cl}_3\text{F}_3\text{N}_2\text{NaO}_2$ , ( $[\text{M} + \text{Na}]^+$ ) 529.0440, Found, 529.0435.

**(E)-4-((3-nitropyridin-2-yl)oxy)-2-phenylbut-2-en-1-yl 2,2,2-trichloroacetimidate (9c) :** 75% yield (3 steps);




yellow oil;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.36 (bs, 1H), 8.31 (dd,  $J = 4.8, 1.7$  Hz, 1H), 8.24 (dd,  $J = 7.9, 2.1$  Hz, 1H), 7.40-7.32 (m, 5H), 7.01 (dd,  $J = 7.9, 4.8$  Hz, 1H), 6.26 (tm,  $J = 6.9$  Hz, 1H), 5.07 (s, 2H), 5.02 (d,  $J = 6.9$  Hz, 2H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  161.4, 154.9, 150.5, 139.6, 135.4, 134.1, 133.2, 127.6, 127.5, 127.2, 123.1, 115.6, 90.3, 70.9, 63.6; IR (ATR,  $\text{cm}^{-1}$ ): 3336, 3081, 2955, 1664, 1602, 1571, 1525, 1464, 1438, 1349, 1299, 1247, 1091, 976, 828, 797, 763, 702, 647; HRMS (ESI $^+$ ) Calcd for  $\text{C}_{17}\text{H}_{14}\text{Cl}_3\text{N}_3\text{NaO}_4$ , ( $[\text{M} + \text{Na}]^+$ ) 451.9948, Found, 451.9942.

#### 7-5-2. Preparation of substrate **1a'**.



**(E)-2-phenyl-4-(2,2,2-trichloro-1-iminoethoxy)but-2-en-1-yl 2,2,2-trichloroacetate (1a') :** 75% yield (3 steps);



yellow oil;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.29 (bs, 1H), 7.40-7.26 (m, 5H), 6.18 (t,  $J = 6.7$  Hz, 1H), 5.11 (s, 2H), 4.78 (d,  $J = 6.5$  Hz, 2H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  162.4, 161.5, 139.7, 135.3, 128.7, 128.6, 128.3, 125.0, 91.2, 89.6, 71.5, 66.0; IR (ATR,  $\text{cm}^{-1}$ ): 3340, 3058, 3027, 2954, 1766, 1663, 1496, 1444, 1292, 1222, 1073, 980, 826, 796, 701, 680, 671, 650; HRMS (ESI $^+$ )

Calcd for  $\text{C}_{14}\text{H}_{11}\text{Cl}_6\text{NNaO}_3$ , ( $[\text{M} + \text{Na}]^+$ ) 437.8768, Found, 437.8762.


## 8. DFT Calculation

### 8-1. Full citation of reference 28.

Gaussian 16, Revision B.01, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. Gaussian, Inc., Wallingford CT, 2016.


### 8-2. Energy profile of the *syn*-S<sub>N</sub>2' pathway

The theoretical calculation of the *syn*-S<sub>N</sub>2' mechanism was conducted. As expected, the energy barrier of the *syn*-S<sub>N</sub>2' was much higher than that of *anti*-S<sub>N</sub>2' mechanism of which pathway was supported by experimental and theoretical studies.



**Figure 6.** The potential energy for the sum of **1a** and **3e** was set to zero. Geometries were optimized and characterized using frequency calculations at the B97D/6-31G(d) level. Gibbs free energies (kcal/mol) in solution phase were calculated using single-point energy calculations at the same level as those for the optimized structures according to the SCRF method based on PCM (CHCl<sub>3</sub>).

### 8-3. 3D structures of the transition states from different angle



**Figure 7.** Transition states of synchronous *anti*-S<sub>N</sub>2' reaction of **1a** catalyzed by (*R*)-**3d**. Geometries were optimized and characterized using frequency calculations at the B97D/6-31G(d) level.











B97D/6-31g(d); E(RB97D) = -5887.048353 hartree  
 Sum of electronic and thermal Free Energies= -5886.466699 hartree  
 Thermal correction to Gibbs Free Energy= 0.581654 hartree  
 pcm(chloroform)/RB97D/6-31g(d); E(RB97D) = -5887.065822 hartree  
 Gibbs Free Energy in toluene = -5886.484168 hartree

Center Number	Atomic Number	Atomic Type	Coordinates (Angstroms)		
			X	Y	Z
1	6	0	-0.117556	6.072411	0.533555
2	6	0	-1.434812	6.516385	0.404395
3	6	0	0.278181	4.797448	0.071983
4	6	0	-2.381375	5.686205	-0.206567
5	6	0	-2.044483	4.393712	-0.653470
6	6	0	-0.713197	3.949861	-0.482766
7	1	0	-3.413009	6.020097	-0.329055
8	6	0	1.723215	4.452984	0.107599
9	6	0	2.677303	5.434530	-0.237305
10	6	0	2.194179	3.181611	0.501539
11	6	0	4.046522	5.160714	-0.173645
12	6	0	3.574363	2.865463	0.556740
13	6	0	4.485093	3.893103	0.221772
14	1	0	5.554047	3.690109	0.297141
15	8	0	-0.365147	2.722821	-1.038440
16	15	0	0.335950	1.461223	-0.224950
17	8	0	1.261806	2.237103	0.914593
18	8	0	1.174695	0.733376	-1.251002
19	7	0	-0.694322	0.508347	0.572755
20	16	0	-1.426594	0.929490	1.976447
21	8	0	-2.577428	0.003958	2.170705
22	8	0	-1.684010	2.388137	2.101990
23	6	0	-0.217018	0.480031	3.254203
24	6	0	0.436483	1.488886	3.973487
25	6	0	0.057531	-0.877713	3.481202
26	6	0	1.393206	1.127882	4.936129
27	6	0	1.014687	-1.227044	4.443905
28	6	0	1.684936	-0.225639	5.169625
29	1	0	2.288197	-0.481214	-0.958176
30	6	0	4.104506	1.529261	0.945655
31	6	0	3.519675	0.736460	1.960485
32	6	0	5.281688	1.044802	0.322691
33	6	0	4.095064	-0.485096	2.338156
34	1	0	2.625275	1.079906	2.471889
35	6	0	5.867639	-0.167740	0.716856
36	1	0	5.735415	1.624211	-0.482997
37	6	0	5.272843	-0.942262	1.727489
38	1	0	3.616148	-1.068137	3.125989
39	1	0	6.779799	-0.511669	0.226320
40	1	0	5.722155	-1.889689	2.028779
41	6	0	-3.105972	3.594770	-1.331966
42	6	0	-3.570197	2.372093	-0.811585
43	6	0	-3.735724	4.130834	-2.476254
44	6	0	4.652479	1.712412	-1.410710
45	1	0	-3.108207	1.964095	0.081315
46	6	0	-4.805336	3.460140	-0.387905
47	1	0	-3.376553	5.078654	-2.882944
48	6	0	-5.269766	2.247133	-2.552752
49	1	0	-5.002586	0.770421	-0.984741
50	1	0	-5.277804	3.886742	-3.975697
51	1	0	-6.109269	1.726975	-3.019605
52	1	0	4.772570	5.933790	-0.431188
53	1	0	2.324745	6.413578	-0.563945
54	1	0	0.634495	6.710699	0.999989
55	1	0	-1.722387	7.501746	0.774958
56	1	0	-0.488082	-1.640199	2.924381
57	1	0	0.196018	2.531319	3.768718
58	1	0	1.911133	1.904783	5.501954
59	1	0	2.428756	-0.501457	5.919920
60	1	0	1.231043	-2.280239	4.636436
61	6	0	0.198294	-2.250026	-0.674957
62	1	0	0.314968	-1.222580	-1.007097
63	1	0	0.641338	-2.500431	0.289825
64	6	0	-0.939784	-2.974489	-1.103034
65	1	0	-2.128580	-3.882825	-0.569557
66	6	0	-1.834204	-2.434309	-2.009525
67	8	0	-3.703333	-3.618598	-0.886143
68	6	0	-3.868700	-2.711444	0.118876
69	7	0	-3.736379	-1.467438	-0.066280
70	1	0	-3.719705	-0.888587	0.782843
71	6	0	-4.130956	-3.471498	1.456063
72	17	0	-4.832159	-2.383439	2.692614
73	17	0	-5.257876	-4.875553	1.206116
74	17	0	-2.513617	-4.105444	2.052585
75	6	0	-1.521732	-1.301313	-2.880224
76	6	0	-2.435149	-0.225903	-2.997606
77	6	0	-0.282853	-1.237427	-3.565662
78	6	0	-2.097713	0.906329	-3.741870
79	1	0	-3.354783	-0.243612	-2.419068
80	6	0	0.031777	-0.117960	4.339575
81	6	0	-0.866999	0.959146	-4.418052
82	1	0	-2.784240	1.752332	-3.765509
83	1	0	0.987132	-0.074305	4.864988
84	1	0	-0.601787	1.846971	-4.995107
85	6	0	-3.220021	-3.049194	-2.122229
86	1	0	-3.938457	-2.311993	-2.503782
87	1	0	-3.187064	-3.905026	-2.814235
88	8	0	1.770744	-2.981245	-1.607484
89	6	0	2.881730	-2.426796	-1.385761
90	7	0	3.071454	-1.188730	-0.972681
91	1	0	4.001754	-0.845890	-0.734106
92	6	0	4.141810	-3.367344	-1.549865
93	17	0	5.627906	-2.454366	-2.051121
94	17	0	3.814376	-4.639690	-2.772044
95	17	0	4.403795	-4.127548	0.081612
96	1	0	0.410507	-2.074199	-3.488557
			88	8	0
			89	6	0
			90	7	0



71	6	0	-2.423242	3.780610	-1.166578	62	1	0	2.475796	3.516413	-2.633813
72	17	0	-2.212079	4.270200	0.591572	63	1	0	2.756260	1.724766	-3.031449
73	17	0	-3.318527	5.105506	-2.050066	64	6	0	1.105617	2.117867	-1.772505
74	17	0	-3.358779	2.275386	-1.256610	65	1	0	0.851343	1.062914	-1.662295
75	6	0	1.673906	3.726163	-0.066629	66	6	0	0.254583	3.054366	-0.935254
76	6	0	1.633304	2.453353	0.548484	67	8	0	-1.219413	4.864597	-1.445388
77	6	0	1.474813	4.882919	0.722418	68	6	0	-1.857673	3.693558	-1.281085
78	6	0	1.447954	2.334040	1.929811	69	7	0	-1.174569	2.633302	-1.047956
79	1	0	1.668219	1.570814	-0.082921	70	1	0	-1.492224	1.039599	-1.118124
80	6	0	1.306296	4.762486	2.105740	71	6	0	-3.379279	3.773181	-1.403813
81	6	0	1.295549	3.491932	2.710365	72	17	0	-3.971948	5.016519	-0.211780
82	1	0	1.411234	1.342395	2.381739	73	17	0	-3.774479	4.306708	-3.096556
83	1	0	1.172002	5.659289	2.713137	74	17	0	-4.151763	2.203759	-1.056467
84	1	0	1.146357	3.403441	3.788068	75	6	0	0.685646	3.046126	0.548849
85	6	0	0.970757	4.765255	-2.299122	76	6	0	2.049292	3.206909	0.857567
86	1	0	1.334246	5.798101	-2.181788	77	6	0	-0.253073	2.986280	1.593642
87	1	0	0.977136	4.493307	-3.365382	78	6	0	2.471513	3.288281	2.190841
88	8	0	3.691311	0.728818	-1.305935	79	1	0	2.786721	3.247950	0.055287
89	6	0	3.906750	0.122644	-0.207954	80	6	0	0.171324	3.083205	2.928198
90	7	0	2.997858	-0.633717	0.354196	81	6	0	1.533147	3.225667	3.232229
91	1	0	3.122226	-1.110842	1.248392	82	1	0	3.535539	3.385362	2.410190
92	6	0	5.275252	0.302012	0.565137	83	1	0	-0.569127	3.040669	3.730241
93	17	0	5.714957	-1.132221	1.572141	84	1	0	1.861540	3.284583	4.271515
94	17	0	5.075638	1.731844	1.680787	85	6	0	0.206193	4.526232	-1.472638
95	17	0	6.605833	0.616901	-0.610268	86	1	0	0.729973	5.246642	-0.836046
96	1	0	1.472338	5.868016	0.254155	87	1	0	0.534246	4.607277	-2.518016

#### CP-6

B97D/6-31g(d); E(RB97D) = -5887.052481 hartree

Sum of electronic and thermal Free Energies= -5886.474044 hartree

Thermal correction to Gibbs Free Energy= 0.578437 hartree

pcm(chloroform)/RB97D/6-31g(d); E(RB97D) = -5887.067698 hartree

Gibbs Free Energy in toluene = -5886.489261 hartree

Center Number	Atomic Number	Atomic Type	Coordinates (Angstroms)		
			X	Y	Z
1	6	0	-0.730685	-5.658328	-1.009454
2	6	0	0.604464	-6.025626	-1.204975
3	6	0	-1.148627	-4.325841	-1.212787
4	6	0	1.543164	-5.070110	-1.613076
5	6	0	1.175709	-3.727402	-1.834695
6	6	0	-0.176335	-3.392333	-1.625079
7	1	0	2.584195	-5.353904	-1.772212
8	6	0	-2.573784	-3.955334	-1.013117
9	6	0	-3.591531	4.804725	-1.496264
10	6	0	-2.968421	-2.785950	-0.326208
11	6	0	-4.940430	-4.495639	-1.294827
12	6	0	-4.320371	-2.442892	-0.100476
13	6	0	-5.296164	-3.331242	-0.604977
14	1	0	-6.347286	-3.102988	-0.424799
15	8	0	-0.582746	-2.070075	-1.883353
16	15	0	-0.925197	-1.090318	-0.626980
17	8	0	-1.982765	-1.968655	0.246211
18	8	0	-1.648178	0.061154	-1.414344
19	7	0	0.231547	-0.545854	0.316325
20	16	0	0.923979	-1.443207	1.542118
21	8	0	2.009175	-0.596085	0.290931
22	8	0	1.240491	-2.828243	1.122690
23	6	0	-0.349243	-1.537391	2.828949
24	6	0	-0.672006	-0.374868	3.542645
25	6	0	-0.974950	-2.763538	3.089295
26	6	0	-1.651887	-0.447697	4.542661
27	6	0	-1.955161	-2.821939	4.091978
28	6	0	-2.294263	-1.667551	4.816701
29	1	0	2.795095	0.885271	-0.495560
30	6	0	-4.749902	-1.219056	0.631434
31	6	0	-4.104814	-0.772452	1.806922
32	6	0	-5.883696	-0.506111	0.175987
33	6	0	-4.583336	0.348368	2.498721
34	1	0	-3.244971	-1.310586	2.196379
35	6	0	-6.365494	0.608049	0.876727
36	1	0	-6.379902	-0.825433	-0.742325
37	6	0	-5.714072	1.042443	2.041906
38	1	0	-4.067314	0.667317	3.405951
39	1	0	-7.238390	1.145894	0.501632
40	1	0	-6.082149	1.916245	2.583292
41	6	0	2.202538	-2.730421	-2.236513
42	6	0	3.447014	-2.714894	-1.570189
43	6	0	1.988545	-1.822741	-3.296474
44	6	0	4.454080	-1.822099	-1.958224
45	1	0	3.600036	-3.381662	-0.721050
46	6	0	3.000139	-0.931620	-3.682642
47	1	0	1.036163	-1.829077	-3.825806
48	6	0	4.237147	-0.927032	-3.017299
49	1	0	5.403168	-1.810849	-1.420309
50	1	0	2.822874	-0.246102	-4.514529
51	1	0	5.014582	-0.216146	-3.298829
52	1	0	-5.716124	-5.163600	-1.672877
53	1	0	-3.303761	-5.703584	-2.042993
54	1	0	-1.465358	-6.392734	-0.676084
55	1	0	0.915761	-7.057874	-1.036572
56	1	0	-0.697316	-3.643605	2.510560
57	1	0	-0.156467	0.558343	3.320390
58	1	0	-1.909589	0.447297	5.113087
59	1	0	-3.059482	-1.717972	5.593532
60	1	0	-2.455056	-3.768646	4.304619
61	6	0	2.153149	2.477894	-2.526475




98	1	0	2. 892480	2. 370397	4. 660122
99	1	0	6. 379170	1. 173199	2. 398261
100	1	0	6. 336236	-0. 909043	1. 105523
101	6	0	4. 725788	-4. 408929	-0. 193532
102	1	0	6. 317612	-2. 959959	-0. 218443
103	1	0	2. 981742	-5. 697898	0. 073252
104	1	0	5. 243146	2. 800924	3. 899273
105	1	0	5. 217933	-5. 087558	-0. 892111
106	6	0	-2. 075762	1. 913795	1. 530878
107	6	0	-2. 146743	2. 860150	0. 516950
108	6	0	-3. 294740	1. 380389	2. 022447
109	6	0	-3. 374381	3. 329885	-0. 032440
110	6	0	-4. 518896	1. 854045	1. 569555
111	6	0	-3. 453737	4. 243080	-1. 125908
112	6	0	-4. 608708	2. 839726	0. 551378
113	6	0	-4. 674969	4. 659061	-1. 629224
114	6	0	-5. 841904	3. 335501	0. 041484
115	6	0	-5. 876410	4. 206123	-1. 033704
116	9	0	-4. 739720	5. 492402	-2. 681499
117	9	0	-2. 342092	4. 708165	-1. 736145
118	9	0	-1. 004145	3. 357587	0. 010325
119	9	0	-3. 315276	0. 394131	2. 927755
120	9	0	-5. 640029	1. 305342	2. 087383
121	9	0	-7. 022963	2. 929673	0. 550767
122	9	0	-7. 052099	4. 598981	-1. 553819
123	6	0	-0. 304301	-2. 443807	6. 389263
124	6	0	-1. 570466	-2. 646585	6. 912419
125	6	0	-4. 079430	-6. 144314	0. 800109
126	6	0	-3. 751856	-7. 019678	1. 820837
127	6	0	-2. 803504	-6. 628429	2. 803605
128	6	0	-2. 225323	-5. 368915	2. 772629
129	6	0	-2. 676980	-2. 837056	6. 040427
130	6	0	-2. 499420	-2. 843626	4. 665972
131	1	0	0. 551405	-2. 275344	7. 047268
132	1	0	-1. 724383	-2. 646907	7. 993265
133	1	0	-3. 677248	-2. 970670	6. 457134
134	1	0	-3. 351110	-2. 979912	4. 000389
135	1	0	-1. 495740	-5. 096229	3. 531125
136	1	0	-2. 520058	-7. 329262	3. 591358
137	1	0	-4. 204564	-8. 012213	1. 863080
138	1	0	-4. 783336	-6. 436020	0. 017012

## 9. Reference


- (1) Y. Ishino; K. Wakamoto; T. Hirashima, *Chem. Lett.*, **1984**, 5, 765–768.
- (2) Joel A. Bergman; Kalub Hahne; Christine A. Hrycyna; Richard A. Gibbs, *Bioorg. Med. Chem. Lett.*, **2011**, 21, 5616-5619.
- (3) (a) Cannon, J. S.; Kirsch, S. F.; Overman, L. E.; Sneddon, H. F. *J. Am. Chem. Soc.* **2010**, 132, 15192-15203. (b) Cannon, J. S.; Olson, A. C.; Overman, L. E.; Solomon, N. S. *J. Org. Chem.* **2012**, 77, 1961–1973.
- (4) (a) Midland, M. M.; Greer, S.; Tramontano, A.; Zderic, S. A. *J. Am. Chem. Soc.* **1979**, 101, 2352-2355. (b) Midland, M. M. B-3-Pinanyl-9-borabicyclo[3.3.1]nonane, *e-EROS Encyclopedia of Reagents for Organic Synthesis* **2001**.

## 10. NMR spectra


$^{19}\text{F}$  NMR (565 MHz) spectra of **S2**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S3




<sup>19</sup>F NMR (565 MHz) spectra of **S3**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of (*R*)-3d




$^{19}\text{F}$  NMR (565 MHz) and  $^{31}\text{P}$  NMR (243 MHz) spectra of (*R*)-**3d**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of (*R*)-3c



$^{19}\text{F}$  NMR (565 MHz) and  $^{31}\text{P}$  NMR (243 MHz) spectra of (*R*)-**3c**




parts per Million : Fluorine19




parts per Million : Phosphorus31


<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1a**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1b**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1c**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1d**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1e**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1f**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1g**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1h**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1i**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1k**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1I**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1m**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1n**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2a**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2b**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2c**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2d**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2e**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2f**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2g**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2h**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2i**



<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2k**




$^1\text{H}$  NMR (600 MHz) and  $^{13}\text{C}$  NMR (150 MHz) spectra of **2l**




S76


<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2m**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **2n**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **5**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **6**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of 7




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **8**



<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S10




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S12




**S84**


<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S13




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S14




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S15




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of *d*-S6




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of (*S*)-*d*-**1a**




$^1\text{H}$  NMR (600 MHz) and  $^{13}\text{C}$  NMR (150 MHz) spectra of (*Z*)-*d*-2a




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of S10




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **9a**




<sup>19</sup>F NMR (565 MHz) spectra of **9a**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **9b**




<sup>19</sup>F NMR (565 MHz) spectra of **9b**



<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **9c**




<sup>1</sup>H NMR (600 MHz) and <sup>13</sup>C NMR (150 MHz) spectra of **1a'**




## 11. HPLC charts


HPLC charts of **2a** (Table 1, entry 12)




HPLC charts of **2b** (Table 2, entry 1)




HPLC charts of **2c** (Table 2, entry 3)




HPLC charts of **2d** (Table 2, entry 4)




HPLC charts of **2e** (Table 2, entry 4)





HPLC charts of **2f** (Table 2, entry 5)





HPLC charts of **2g** (Table 2, entry 6)





HPLC charts of **2h** (Table 2, entry 7)




HPLC charts of **2i** (Table 2, entry 8)




HPLC charts of **2k** (Table 2, entry 10)




HPLC charts of **2l** (Table 2, entry 11)




HPLC charts of **2m** (Table 2, entry 12)




HPLC charts of **2n** (Table 2, entry 13)




HPLC charts of **5** (Scheme 2)



HPLC charts of **6** (Scheme 2)



HPLC charts of **8** (Scheme 2)



HPLC charts of *(R)*-*(Z)*-*d*-**2a** (Scheme 3)

